Latest Earnings Results: Q3 '26
Estimated EPS
-$0.05
Reported EPS
-$0.04
Surprise
+11.11%
Estimated Rev
$1.43M
Reported Rev
$0.45M
Surprise
-68.67%
Dyadic expects to receive the $225,000 milestone payment and recognize it as revenue in the fourth quarter of 2026, following the first commercial sale of its second chymosin product.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.04 | -- | -- | N/A |
Q3 '26 | -$0.05 | -$0.04 | 11.11% | BEAT |
Q2 '26 | -$0.04 | -$0.06 | -71.43% | MISSED |
Q1 '26 | -$0.04 | -$0.05 | -25.00% | MISSED |
Q4 '25 | -$0.05 | -$0.04 | 11.11% | BEAT |